Key contacts

Haran Siva
Director

Regional office - Australia
Level 12, office 1205
95 Pitt Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 8249 8342

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research

Green Dragon Gas

ODP submission: Green shoots

Update | Oil & Gas | 28/04/2017

2017 is likely to be a critical year for Green Dragon Gas (GDG) as management works to deliver on several milestones that will enable a step-up in activity levels. We were encouraged by the CNPC approval and submission of the GCZ CBM Block overall development plan (ODP) in April. Execution of supplementary agreements and GSS ODP submission would provide an incremental reserve base for GDG to leverage in order to refinance outstanding bonds and fund further drilling activity. With regard to funding…

CoAssets

Termination of coverage

Update | Technology | 20/04/2017

Edison Investment Research is terminating coverage on CoAssets (CA8). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Viralytics

Cavatak/Yervoy combo enters the spotlight

Outlook | Pharmaceutical & healthcare | 19/04/2017

Viralytics’ presentations at AACR highlighted an impressive 36% response rate when melanoma patients refractory to the best available PD1/L1 checkpoint inhibitor therapy were treated with its Cavatak virotherapy plus Yervoy. It has expanded the Phase Ib MITCI trial to recruit an extra 44 patients who have failed prior PD1/L1 therapy, which could put it on track to a pivotal study or even provide a potential pathway to accelerated approval. The CAPRA study of Cavatak plus Keytruda in melanoma…

Galaxy Resources

Termination of coverage

Update | Mining | 12/04/2017

Edison Investment Research is terminating coverage on Galaxy Resources (GXY). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Cradle Resources

Termination of coverage

Update | Mining | 12/04/2017

Edison Investment Research is terminating coverage on Cradle Resources (CXX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports